PubRank

Bernhard Hemmer

Author PubWeight™ 189.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 13.23
2 Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009 6.96
3 Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009 4.88
4 Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013 4.62
5 TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003 4.17
6 Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006 3.38
7 Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012 3.12
8 Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012 2.90
9 Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006 2.62
10 γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity 2010 2.54
11 Acute disseminated encephalomyelitis: an update. Arch Neurol 2005 2.45
12 An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 2011 2.31
13 Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2005 2.17
14 Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol 2012 2.15
15 Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol 2013 2.00
16 Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005 1.95
17 Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005 1.92
18 Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008 1.88
19 Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006 1.79
20 Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013 1.76
21 Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011 1.72
22 Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 2007 1.63
23 EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet 2010 1.62
24 NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol 2008 1.59
25 Boxing-acute complications and late sequelae: from concussion to dementia. Dtsch Arztebl Int 2010 1.59
26 Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009 1.55
27 A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005 1.50
28 Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014 1.45
29 Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012 1.44
30 Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006 1.43
31 Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009 1.42
32 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010 1.37
33 Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002 1.37
34 Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010 1.35
35 Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol 2007 1.34
36 Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002 1.29
37 CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 2012 1.29
38 Spatiotemporal reconfiguration of large-scale brain functional networks during propofol-induced loss of consciousness. J Neurosci 2012 1.28
39 Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2009 1.28
40 Simultaneous electroencephalographic and functional magnetic resonance imaging indicate impaired cortical top-down processing in association with anesthetic-induced unconsciousness. Anesthesiology 2013 1.26
41 Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int 2011 1.26
42 Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008 1.25
43 Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009 1.24
44 Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013 1.22
45 Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009 1.22
46 Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One 2011 1.13
47 Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005 1.13
48 The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 2009 1.12
49 The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2010 1.12
50 Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol 2010 1.12
51 Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010 1.11
52 The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol 2003 1.10
53 The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol 2010 1.09
54 Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007 1.09
55 Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004 1.09
56 Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol 2007 1.08
57 Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 2010 1.06
58 Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011 1.02
59 The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun Rev 2011 1.02
60 TNF-alpha induced NFκB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 2011 1.01
61 Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol 2009 1.01
62 Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol 2011 0.98
63 HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008 0.98
64 Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation 2011 0.97
65 Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007 0.96
66 Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ 2010 0.96
67 Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013 0.96
68 Neurofilament ELISA validation. J Immunol Methods 2009 0.96
69 Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res 2009 0.95
70 Prognostic value of the ABCD2 score beyond short-term follow-up after transient ischemic attack (TIA)--a cohort study. BMC Neurol 2010 0.95
71 Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015 0.94
72 Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One 2010 0.93
73 EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother 2010 0.93
74 Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Mult Scler 2011 0.93
75 Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology 2014 0.93
76 Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des 2012 0.92
77 The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 2008 0.91
78 Gene expression profiles derived from single cells in human postmortem brain. Brain Res Brain Res Protoc 2004 0.91
79 Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007 0.91
80 A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics 2002 0.91
81 White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler 2013 0.90
82 Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. Am J Ophthalmol 2004 0.90
83 Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol 2007 0.89
84 Enriched CD161high CCR6+ γδ T cells in the cerebrospinal fluid of patients with multiple sclerosis. JAMA Neurol 2013 0.89
85 Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun 2010 0.88
86 Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. Eur J Immunol 2007 0.88
87 High throughput analysis of TCR-beta rearrangement and gene expression in single T cells. Lab Invest 2006 0.88
88 Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol 2014 0.88
89 Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol 2006 0.87
90 Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler 2007 0.87
91 High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 2005 0.86
92 Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain 2010 0.86
93 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. J Nucl Med 2012 0.86
94 JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 2014 0.86
95 Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation. J Neuroimmunol 2006 0.86
96 CD8 T-cell subsets and viral load in the cerebrospinal fluid of therapy-naive HIV-infected individuals. AIDS 2007 0.84
97 Pharmacological treatment of early multiple sclerosis. Drugs 2008 0.84
98 Myoclonus-dystonia in 18p deletion syndrome. Mov Disord 2010 0.84
99 Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008 0.84
100 Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009 0.84
101 Multiple sclerosis--novel insights and new therapeutic strategies. Curr Opin Neurol 2005 0.84
102 Mitochondrial membrane protein associated neurodegenration: a novel variant of neurodegeneration with brain iron accumulation. Mov Disord 2012 0.83
103 Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 2002 0.83
104 MRI plaque imaging detects carotid plaques with a high risk for future cerebrovascular events in asymptomatic patients. PLoS One 2013 0.82
105 Multiple sclerosis and the autonomic nervous system. J Neurol 2006 0.82
106 The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation 2013 0.82
107 The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther 2010 0.82
108 α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun 2014 0.81
109 Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. J Neuroimmunol 2013 0.81
110 The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomy. Neurochem Res 2009 0.81
111 Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005 0.81
112 Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011 0.81
113 Thyroid antibodies in aquaporin-4 antibody positive central nervous system autoimmunity and multiple sclerosis. Clin Endocrinol (Oxf) 2011 0.81
114 Clonal accumulation of activated CD8+ T cells in the central nervous system during the early phase of neuroborreliosis. J Infect Dis 2003 0.81
115 Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system. J Immunol 2010 0.80
116 Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol 2013 0.80
117 Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatr Dis Treat 2013 0.80
118 Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Rev Clin Immunol 2014 0.80
119 Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol 2004 0.80
120 Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine 2012 0.80
121 To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler 2014 0.80
122 High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes. Arch Neurol 2007 0.80
123 Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010 0.79
124 Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J Neurol 2005 0.79
125 High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. J Neurol 2009 0.79
126 Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch Neurol 2010 0.79
127 Biomarkers of treatment response in multiple sclerosis. Expert Rev Neurother 2014 0.78
128 Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008 0.78
129 The antibody response to oligodendrocyte specific protein in multiple sclerosis. J Neuroimmunol 2010 0.78
130 Cerebral vasculitis mimicking migraine with aura in a patient with Crohn's disease. Acta Neurol Belg 2009 0.78
131 Transcranial Doppler ultrasonography predicts cardiovascular events after TIA. BMC Med Imaging 2009 0.78
132 Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler 2013 0.78
133 A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors. Biochim Biophys Acta 2011 0.78
134 Specificity and degeneracy: T cell recognition in CNS autoimmunity. Mol Immunol 2004 0.78
135 A 32-year-old man with relapsing-progressive brainstem symptoms. Lancet Neurol 2006 0.77
136 Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochem Int 2010 0.77
137 The role of the Epstein-Barr virus receptor CD21 in multiple sclerosis. J Neuroimmunol 2011 0.77
138 Analysis of the stathmin rs182455 single nucleotide promoter polymorphism in patients with multiple sclerosis. J Neurogenet 2008 0.77
139 Clinicopathological considerations in acute disseminated encephalomyelitis (ADEM): a fulminant case with favorable outcome. J Neurol 2011 0.77
140 Myositis in a patient with large granular leukocyte leukemia. Muscle Nerve 2004 0.76
141 Viral pathogens in multiple sclerosis: an intriguing (hi)story. Arch Neurol 2004 0.76
142 Systemic thrombolysis in ischemic stroke after recent oral surgery and management of oral cavity bleeding. Ann Emerg Med 2011 0.76
143 Lack of association between right-to-left shunt and cerebral ischemia after adjustment for gender and age. J Negat Results Biomed 2008 0.76
144 Sibling disability risk at onset and during disease progression in familial multiple sclerosis. Mult Scler 2011 0.75
145 Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opin Biol Ther 2014 0.75
146 Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide. J Neuroinflammation 2011 0.75
147 Reply to Dr Pandey. Ann Neurol 2013 0.75
148 The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. J Neuroimmunol 2004 0.75
149 Time to talk about timing--when to start, stop and change anti-migratory drugs in MS. Mult Scler 2012 0.75
150 Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler 2012 0.75
151 No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis. Arch Neurol 2011 0.75
152 Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis. Acta Neurol Belg 2012 0.75
153 Corrigendum: Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol 2017 0.75